Skip to content

A Nested Case Control study of vascular endothelial inflammatory factors predicting cardiovascular related disease in HIV infected patients

A Nested Case Control study of vascular endothelial inflammatory factors predicting cardiovascular related disease in HIV infected patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083269
Enrollment
Unknown
Registered
2024-04-19
Start date
2022-12-12
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS

Interventions

CVD group:none
non-CVD group:none

Sponsors

Beijing Youan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age =18 years old; (2) WB confirmation test is positive: at least two env bands (gp41 and gp160/gp120) appear, or at least one env band and p24 band appear simultaneously; (3) The duration of ART treatment exceeds 5 years; (4) Patients diagnosed with three common cardiovascular diseases (hypertension, moderate and severe hyperlipidemia, coronary heart disease) were selected as the experimental group, and patients excluded from cardiovascular disease were selected as the control group. Baseline characteristics such as age, gender, and HIV diagnosis time of the control group were matched with those of the experimental group; (5) Voluntarily sign informed consent and ensure follow-up; (6) unplanned relocation from Beijing during the course of the test.

Exclusion criteria

Exclusion criteria: (1) Patients who are allergic to or intolerant to therapeutic drugs; (2) Active opportunistic infection (stipulated in the National AIDS Treatment Guidelines) or AIDS-related malignant tumor at the time of enrollment; Or had an opportunistic infection within 3 months before inclusion, and the condition was still unstable within 2 weeks before inclusion; (3) Patients with serious mental and neurological diseases; (4) pregnant and lactating women; (5) Failure to comply with the experimental agreement and withdrawal of the informed consent; (6) Those found in the course of research to have lied to the data or concealed their true personal situation.

Design outcomes

Primary

MeasureTime frame
IL-6;

Secondary

MeasureTime frame
antiretroviral therapy;CD4+T cell count;Viral load;demographic baseline characteristics;

Countries

China

Contacts

Public ContactXiaojie Huang

Beijing Youan Hospital, Capital Medical University

huangxiaojie78@126.com+86 136 8114 4481

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026